EU still holds out on granting approval to Oxford-AstraZeneca's COVID-19 vaccine

The coronavirus vaccine developed by AstraZeneca and Oxford University, which was approved Wednesday in Britain, is unlikely to get a green light in the European Union in the next month, according to the European Medicines Agency (EMA). The regulator, charged with overseeing vaccines' authorisation in the EU before they can be marketed, approved the Pfizer-BioNTech vaccine on December 21. It is expected to rule on Moderna's vaccine on January 6. But an EU ruling on the AstraZeneca-Oxford jab will take some time.

"Additional scientific information on issues related to quality, safety and efficacy of the vaccine is deemed necessary to support the rigour required for a conditional marketing authorisation (CMA) and this has been requested from the company," the EMA said in a statement. "Further information from the ongoing clinical trials is also expected from January."

The Amsterdam-based agency earlier told AFP that it had not yet received any formal marketing authorisation and that it had set no timetable for approving the vaccine.

The regulator's deputy executive director Noel Walthion told Belgian newspaper Het Nieuwsblad on Tuesday that a possible approval in January is "unlikely".

The AstraZeneca-Oxford vaccine is currently undergoing a "rolling review" which allows the EMA to examine safety and efficacy data as they are released, even before a formal application for authorisation is filed by the manufacturer.

This procedure speeds up the evaluation of a marketing authorisation application once it is made, the EMA said.

The agency said Wednesday it is "aware that the UK MHRA has granted a temporary authorisation of supply of the vaccine in the emergency use setting, which is distinct from a marketing authorisation."

An AstraZeneca spokesperson told AFP it "has submitted a full data package to support an application for conditional marketing authorisation for the AstraZeneca Covid-19 vaccine to the European Medicines Agency."

The spokesperson added: "AstraZeneca has been submitting data on a rolling basis and will continue to work closely with the EMA to support the start of a formal CMA application process."

Britain is the first country in the world to approve the vaccine, which is cheaper to produce and easier to store and transport than the Pfizer-BioNTech jab.

For EU countries, it is up to the European Commission in Brussels to issue the final green light after EMA approval.

Inoculations with the Pfizer-BioNTech vaccine began in the 27-member bloc over the weekend.



from Firstpost Tech Latest News https://ift.tt/2LcwxEb

Comments

Post a Comment

Popular posts from this blog

Elon Musk’s bid spotlights Twitter’s unique role in public discourse – and what changes might be in store

Twitter has been in the news a lot lately, albeit for the wrong reasons. Its stock growth has languished and the platform itself has largely remained the same since its founding in 2006. On April 14, 2022, Elon Musk, the world’s richest person, made an offer to buy Twitter and take the public company private. In a filing with the Securities and Exchange Commission , Musk stated, “I invested in Twitter as I believe in its potential to be the platform for free speech around the globe, and I believe free speech is a societal imperative for a functioning democracy.” As a researcher of social media platforms , I find that Musk’s potential ownership of Twitter and his stated reasons for buying the company raise important issues. Those issues stem from the nature of the social media platform and what sets it apart from others. What makes Twitter unique Twitter occupies a unique niche. Its short chunks of text and threading foster real-time conversations among thousands of people, which
Read more

To reach net-zero emissions and remove CO2 from the air, scientists drawn up six priorities

Image
To reach net-zero emissions by 2050, global emissions must be cut faster and deeper than the world has yet managed. But even then, some hard-to-treat sources of pollution – in aviation, agriculture and cement making – may linger for longer than we would like. It will take time for clean alternatives to arrive and replace them. That means the world also needs to find and ramp up ways of taking CO₂ out of the atmosphere to stabilise the climate. Just meeting the UK’s net-zero target is likely to require the removal of 100 million tonnes of CO₂ a year , similar in size to current emissions from the country’s largest-emitting sector, road transport, but in reverse. The UK government’s announcement of £31.5 million (US$44.7 million) in support for research and development of carbon removal is welcome. And while trials of new tech will help, there are many social issues that need to be tackled if removing greenhouse gases is to succeed. Done right, carbon removal could be the perfect a
Read more

NASA is planning to partner with SpaceX to reboost the Hubble Telescope and extend its life

Image
The Hubble Space Telescope is one of the most important scientific achievements of the human species that has helped us understand space. It has been in orbit for over 30 years and has been feeding some of the most vital streams of information that has not only helped us steer our space exploration efforts, but also solve some of the more deep mysteries of the universe . NASA would love to extend its usable life for as long as possible. Unfortunately, for some years now, Hubble Space Telescope has been slipping out of its orbit. That is why, NASA is planning to team up with Elon Musk’s SpaceX and place it into a higher much more stable orbit. NASA, SpaceX and Jared Isaacman, a private astronaut with the Polaris Program, hosted a media teleconference on Thursday to announce a feasibility study that will look into sending a commercial Dragon spacecraft to reboost the Hubble Space Telescope . This will, in effect place the telescope into a higher and more stable orbit than it’s curren
Read more